Driverless semis traveling from Dallas to Houston — originally expected to launch this year — have been put in park until April. Photo courtesy of Aurora

Autonomous truck company Aurora Innovation says it won't start hauling freight without humans on board until April of next year, a delay from previous statements that commercial service would begin by the end of 2024.

The Pittsburgh company on Wednesday said the April launch of driverless semis traveling from Dallas to Houston — originally announced last year — will be “modestly later” than the company had intended. The company also previously announced a partnership with Uber.

The company told investors on its third-quarter earnings conference call that it has made progress toward ensuring its trucks will operate safely.

Remaining obstacles are “primarily in the areas of some elements of surface street driving and some elements of construction that we see on the freeway,” CEO Chris Urmson said. “We want to have extremely high confidence in the system as we as we go forward.”

The company will start with about 10 autonomous tractor-trailers and move to “tens” of trucks by the end of next year, Urmson said.

“This shift to our timeline will have a negligible financial impact and does not affect our scaling efforts on our path to self-funding," Urmson said.

Aurora also intends to haul freight without human drivers from Fort Worth, Texas, to Phoenix later in 2025, Urmson said.

Aurora in August added nearly $500 million to its balance sheet with a capital raise in August, which the company expects to fund the initial phases of its strategy to scale up driverless trucking.

The new program hopes to democratize self-driving freight trucks. Photo courtesy of Aurora

Autonomous freight co. with Houston-Dallas pilot opens early access program

join the fleet

Texas has been a key testing area for autonomous freight technology for years, and one major player in the space has made its latest move to put the pedal to the metal on self-driving trucking.

Aurora Innovation (NASDAQ: AUR) announced a new program with Uber Freight. Premier Autonomy, which will provide "early access to over 1 billion of Aurora’s driverless miles to Uber Freight carriers through 2030," is launching to deploy autonomous freight vehicles on the Uber Freight network.

Uber Freight, an end-to-end logistics company managing over $18 billion of freight, is also reportedly going to be among Aurora's first customers for its Dallas-to-Houston freight route that anticipates driverless hauls beginning at the end of 2024.

“Uber Freight and Aurora see a tremendous opportunity to democratize autonomous trucks for carriers of all sizes, enabling them to drive more revenue, scale their fleets, and strengthen their bottom lines,” Lior Ron, founder and CEO of Uber Freight, says in a news release. “Autonomous trucks will make moving goods more efficient, and this industry-first program will help facilitate and accelerate the adoption of autonomous trucks with our carriers. We’re proud to work alongside the amazing team at Aurora to bring this technology into the hands of carriers and ultimately usher in a new era of logistics.”

The new program, a first for the industry, allows customers to purchase and begin implementing Aurora Driver, a self-driving system that can work with multiple vehicle types, including freight trucks and passenger vehicles. Aurora provides driver-as-a-service products for trucking and ride-hailing industries and has a slew of partners in addition to Uber and Uber Freight, including FedEx, Toyota, Volvo Trucks, Volvo Autonomous Solutions, and more.

“With Uber Freight, we can provide hundreds of carriers priority access to autonomous truck capacity that they wouldn’t otherwise have. Working with carriers of all sizes is one of the many ways we will transform the industry and see thousands of driverless trucks on the road,” Ossa Fisher, president of Aurora, says in the release. “It’s exciting and validating that companies like Uber Freight are reserving our long-term capacity for their customers. We all see collective value in this offering.”

With enrollment into the new Premier Autonomy Program, customers receive a subscription to the Aurora Driver for autonomous freight hauling, the opportunity to access over 1 billion driverless miles through 2030, and access to autonomous trucks via a planned, seamless integration of the Aurora Driver into the Uber Freight platform, according to the news release.

Since 2020, Uber Freight and Aurora have hauled millions of pounds of cargo through their pilot program that operated on the Dallas-Houston route.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.